TR201910573T4 - Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler. - Google Patents

Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler. Download PDF

Info

Publication number
TR201910573T4
TR201910573T4 TR2019/10573T TR201910573T TR201910573T4 TR 201910573 T4 TR201910573 T4 TR 201910573T4 TR 2019/10573 T TR2019/10573 T TR 2019/10573T TR 201910573 T TR201910573 T TR 201910573T TR 201910573 T4 TR201910573 T4 TR 201910573T4
Authority
TR
Turkey
Prior art keywords
staphylococcus aureus
against staphylococcus
immunize against
stabilized proteins
cysteine
Prior art date
Application number
TR2019/10573T
Other languages
English (en)
Inventor
Bagnoli Fabio
Falugi Fabiana
Grandi Guido
Mariani Massimo
Nissum Mikkel
Pallaoro Michele
Savino Silvana
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of TR201910573T4 publication Critical patent/TR201910573T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Sistein içeren S.aureus antijenlerinin disülfür bağ oluşumunun ortadan kaldırılması antijen kararlılığını geliştirmektedir. Buluş, sistein tortusunu ikame eden, çıkaran veya modifiye eden bir nokta mutasyonu ile sistein içeren S.aureus antijeninin varyant formlarını sağlamaktadır.
TR2019/10573T 2012-08-31 2013-08-29 Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler. TR201910573T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261695723P 2012-08-31 2012-08-31

Publications (1)

Publication Number Publication Date
TR201910573T4 true TR201910573T4 (tr) 2019-08-21

Family

ID=49036594

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/10573T TR201910573T4 (tr) 2012-08-31 2013-08-29 Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler.

Country Status (15)

Country Link
US (1) US9926344B2 (tr)
EP (1) EP2890394B1 (tr)
JP (1) JP6435261B2 (tr)
CN (2) CN104619336A (tr)
CY (1) CY1121944T1 (tr)
DK (1) DK2890394T3 (tr)
ES (1) ES2737024T3 (tr)
HR (1) HRP20191166T1 (tr)
HU (1) HUE044211T2 (tr)
LT (1) LT2890394T (tr)
PL (1) PL2890394T3 (tr)
PT (1) PT2890394T (tr)
SI (1) SI2890394T1 (tr)
TR (1) TR201910573T4 (tr)
WO (1) WO2014033190A1 (tr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014002363A (es) * 2011-09-01 2014-04-14 Novartis Ag Formulaciones de antigenos de staphylococcus aureus con adyuvante.
LT3122378T (lt) 2014-03-26 2020-02-10 Glaxosmithkline Biologicals S.A. Mutantų stafilokokiniai antigenai
EP3538266A4 (en) 2016-11-14 2020-06-17 Lilac Solutions, Inc. LITHIUM EXTRACTION WITH COATED ION EXCHANGE PARTICLES
JP6916042B2 (ja) * 2017-06-09 2021-08-11 株式会社明治 抗原特異的インターフェロンγ産生促進用組成物
CN111163852A (zh) 2017-08-02 2020-05-15 锂莱克解决方案公司 使用多孔离子交换珠进行的锂提取
JP7427598B2 (ja) 2018-02-28 2024-02-05 ライラック ソリューションズ，インク． リチウム抽出用の粒子トラップを備えたイオン交換反応器
CA3166921A1 (en) 2020-01-09 2021-07-15 Lilac Solutions, Inc. Process for separating undesirable metals
CN111595658B (zh) * 2020-06-06 2023-11-14 宾傲 一种提取细胞中蛋白的裂解液及其制备方法
KR20230023714A (ko) 2020-06-09 2023-02-17 리락 솔루션즈, 인크. 스케일런트의 존재 하에서의 리튬 추출
EP4247759A1 (en) 2020-11-20 2023-09-27 Lilac Solutions, Inc. Lithium production with volatile acid
EP4326413A1 (en) 2021-04-23 2024-02-28 Lilac Solutions, Inc. Ion exchange devices for lithium extraction

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS624300A (ja) * 1985-06-28 1987-01-10 Dai Ichi Seiyaku Co Ltd 改良型ヒトガンマインタ−フエロンおよびその製造方法
ATE198353T1 (de) * 1988-08-24 2001-01-15 American Cyanamid Co Stabilisierung von somatotropinen durch modifikation von cystein-resten durch orts- spezifische mutagenese oder chemische derivatisierung
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5874238A (en) * 1993-02-26 1999-02-23 Immtech International Inc. Mutant protein and methods and materials for making and using it
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
WO1999056776A2 (en) 1998-05-07 1999-11-11 Corixa Corporation Adjuvant composition and methods for its use
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
GB9825421D0 (en) * 1998-11-19 1999-01-13 Isis Innovation Process for oxidising terpenes
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
KR100382239B1 (ko) * 2000-02-17 2003-04-26 주식회사 엘지생명과학 황색 포도상 구균의 변이 독소 에스이씨-에스이알, 그것의발현벡터 및 숙주세포, 그 생산방법 및 백신제조방법
IL152804A0 (en) * 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
KR20070008625A (ko) 2004-04-05 2007-01-17 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
WO2007044382A2 (en) * 2005-10-07 2007-04-19 Health Protection Agency Proteins with improved solubility and methods for producing and using same
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
CA2637598A1 (en) 2006-01-18 2007-02-14 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
CN101522218B (zh) 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
UY31930A (es) * 2008-06-25 2010-01-29 Boheringer Ingelheim Pharma Kg Pestivirus atenuados recombinantes, en particular a csfv, bvdv o bdv atenuado recombinante
PL2510947T3 (pl) * 2009-04-14 2016-09-30 Kompozycje do immunizacji przeciwko Staphylococcus aureus
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
CA2779798C (en) * 2009-09-30 2019-03-19 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
JP5914344B2 (ja) 2009-10-30 2016-05-11 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ５型および８型の莢膜糖の精製
JP2011212008A (ja) * 2010-03-16 2011-10-27 Olympus Corp 蛍光タンパク質およびｐＨ測定方法
MX2014002363A (es) * 2011-09-01 2014-04-14 Novartis Ag Formulaciones de antigenos de staphylococcus aureus con adyuvante.
CN104023744A (zh) 2011-12-23 2014-09-03 诺华股份有限公司 用于针对金黄色葡萄球菌免疫的稳定组合物

Also Published As

Publication number Publication date
US20150203542A1 (en) 2015-07-23
WO2014033190A1 (en) 2014-03-06
HUE044211T2 (hu) 2019-10-28
PL2890394T3 (pl) 2019-12-31
ES2737024T3 (es) 2020-01-09
PT2890394T (pt) 2019-07-15
EP2890394A1 (en) 2015-07-08
US9926344B2 (en) 2018-03-27
JP6435261B2 (ja) 2018-12-05
LT2890394T (lt) 2019-07-25
HRP20191166T1 (hr) 2019-10-04
DK2890394T3 (da) 2019-07-15
EP2890394B1 (en) 2019-05-01
CY1121944T1 (el) 2020-10-14
SI2890394T1 (sl) 2019-06-28
JP2015528455A (ja) 2015-09-28
CN110563818A (zh) 2019-12-13
CN104619336A (zh) 2015-05-13

Similar Documents

Publication Publication Date Title
TR201910573T4 (tr) Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler.
CY1121832T1 (el) Μονοκλωνικα αντισωματα κατα του παραγοντα αναπτυξεως και διαφοροποιησεως 15(gdf-15)
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
EA201790359A1 (ru) Пирролобензодиазепины и их конъюгаты, связанные дисульфидной связью с антителами
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
EA202092435A2 (ru) Моноклональные антитела против bcma
MX2022010324A (es) Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201690667A1 (ru) Композиции, содержащие антитело к pdl1
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201691266A1 (ru) Анти-cd3 антитела и способы применения
EA201590171A1 (ru) ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b
EA201590172A1 (ru) ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b
EA201590174A1 (ru) Иммуноконъюгаты, содержащие анти-cd22 антитела
EA201590173A1 (ru) Иммуноконъюгаты, содержащие антитела к cd22
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA202090683A2 (ru) Способы и композиции для лечения рака